Quick Answer
Monte Rosa Therapeutics, Inc. reported Stockholders Equity of $233.06 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $233.06M | +4.5% |
| 2024 | $222.94M | +24.4% |
| 2023 | $179.25M | -34.0% |
| 2022 | $271.41M | -21.9% |
| 2021 | $347.51M | +813.2% |
| 2020 | -$48.73M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $245.84M | +19.7% | -8.3% |
| June 30, 2025 | $268.08M | +19.3% | -2.6% |
| March 31, 2025 | $275.16M | +80.4% | +23.4% |
| December 31, 2024 | $222.94M | +24.4% | +8.5% |
| September 30, 2024 | $205.46M | +11.3% | -8.6% |
| June 30, 2024 | $224.67M | +5.2% | +47.3% |
| March 31, 2024 | $152.52M | -37.4% | -14.9% |
| December 31, 2023 | $179.25M | -34.0% | -2.9% |
- Monte Rosa Therapeutics, Inc. showed an increase of +4.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s stockholders equity has grown by 578.3% (from -$48.73 million to $233.06 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: